ExpressionEdits

A warm welcome to Amrik, our new CSO 👏

Come and join our relatively small but certainly mighty team !

Last Saturday was #InternationalWomensDay, today, we're spotlighting the incredible women driving big name scale-ups: Abound, Deblock, ExpressionEdits, Little Journey, Luminance, PocDoc, Sano Genetics, SOLASTA Bio, and Xampla. They’re all breaking barriers in their respective industries in 2025 – and beyond 🙌 Representation matters. When young girls see women leading in fields like tech, finance, and healthcare, it shows them that they can do it too 👩🏻💻👩🏻💼👩🏽⚕️ Discover our latest blog to learn more about these amazing women, and why their stories are so important for the next generation of leaders: https://lnkd.in/d6ZP75_4 Michelle He, PhD, CFA, Adriana Restrepo, Sophie Copley, Eleanor Lightbody, Kiran Roest, Charlotte Guzzo, Kärt Tomberg, Liliana Antunes, Shireen Davies, Alexandra French #WomenInBusiness #FemaleFounders #ScaleUp50

Pharmaceutical Business Review covers ExpressionEdits: The collaboration marks the expansion of ExpressionEdits’ intronisation technology from protein-based therapeutics into the gene therapy sector. ExpressionEdits CEO and co-founder Dr Kärt Tomberg said: “Our platform harnesses the potential of introns to overcome challenges in gene expression, enabling therapies that were previously limited by poor expression and narrow design options https://lnkd.in/epwXyBR5

🤝 Congratulations to ExpressionEdits on their new collaboration with Boehringer Ingelheim to advance gene therapy through AI-powered intron optimisation! "This week, the company announced its first collaboration and licensing agreement with a major pharmaceutical company, Boehringer Ingelheim, that is focused on developing enhanced gene therapies. Under the terms of the partnership, Boehringer will leverage ExpressionEdits’ Genetic Syntax Engine, an AI-powered platform that generates optimized introns that boost protein expression without altering the underlying genetic sequence. The partners are not disclosing which therapies they will collaborate on at this time." What a milestone on the journey to bring better therapies to market faster - Kärt Tomberg, Rebecca Godfrey, Leopold Parts, Allan Bradley and team. Read more here: https://lnkd.in/eUtq9WzN

Business Weekly newspaper covers ExpressionEdits and Boehringer Ingelheim collaboration: 🧬🧬 Boehringer will leverage ExpressionEdits’ Genetic Syntax Engine, a proprietary AI-powered platform that uses optimised introns to enhance gene expression without altering the underlying genetic sequence, for two gene therapy targets. Gene therapies are often limited by low effectiveness due to insufficient expression of the therapeutic protein, leading to the need for high viral loads or repeated dosing. ExpressionEdits has developed a novel approach to enhance therapeutic gene expression by restoring introns, called intronization. Read the article: https://lnkd.in/dj-VDEDR

ExpressionEdits in Cambridge has clinched unspecified riches from global pharmaceutical company Boehringer Ingelheim through a collaboration and licensing agreement. Boehringer will leverage ExpressionEdits’ Genetic Syntax Engine, a proprietary AI-powered platform that uses optimised introns to enhance gene expression without altering the underlying genetic sequence, for two gene therapy targets. ExpressionEdits will receive undisclosed payments during the collaboration and is eligible to receive potential additional success based preclinical, clinical and commercial milestone-based payments. Gene therapies are often limited by low effectiveness due to insufficient expression of the therapeutic protein, leading to the need for high viral loads or repeated dosing. ExpressionEdits has developed a novel approach to enhance therapeutic gene expression by restoring introns, called intronization. “We’re thrilled to announce our partnership with Boehringer Ingelheim,” said Dr Kärt Tomberg, CEO and Co-Founder, ExpressionEdits. “Our platform harnesses the potential of introns to overcome challenges in gene expression, enabling therapies that were previously limited by poor expression and narrow design options. “Joining forces with the scientists at Boehringer Ingelheim will enable us to advance first-in-class gene therapies for patients with high medical need.” Full article – https://lnkd.in/dDqa6dcp

Thank you Genetic Engineering & Biotechnology News for speaking with our CEO Kärt Tomberg on our collaboration with Boehringer Ingelheim in #genetherapy. Read the article by Uduak Grace Thomas: https://lnkd.in/eUtq9WzN

🚀 Big news! ExpressionEdits is partnering with Boehringer Ingelheim to enhance gene therapies with our AI-powered Genetic Syntax Engine and #intronization technology. By increasing transgene expression, we’re tackling one of gene therapy’s biggest challenges — boosting potency while reducing high viral loads and repeat dosing. Intron-driven expression also unlocks the full potential of tissue-specific promoters, enabling more targeted therapies. This collaboration will enable us to unlock new possibilities in gene therapy and bring first-in-class treatments to patients in need. Read our press release: https://lnkd.in/exiCXWJu #GeneTherapy #Innovation #biotechnews

Excited that ExpressionEdits has been included in Capsule Insurance’s Scale-Up 50 2025, showcasing the UK’s hottest tech scale-ups to watch!